Drug approval : entrectinib and larotrectinib - cancers with NTRK fusion

被引：2
|
作者：
Delaye, Matthieu [1 ,2 ]
Rodrigues, Manuel [3 ,4 ]
机构：
[1] Hop Tenon, Serv Oncol Med & Therapie Cellulaire, 4 Rue Chine, F-75020 Paris, France
[2] Assoc Enseignement & Rech Internes Oncol AERIO, 149 Ave Maine, F-75014 Paris, France
[3] PSL Res Univ, Inst Curie, Dept Oncol Med, 26 Rue Ulm, F-75005 Paris, France
[4] PSL Res Univ, Inst Curie, INSERM, U830, 26 Rue Ulm, F-75005 Paris, France
来源：
BULLETIN DU CANCER | 2020年 / 107卷 / 11期
关键词：
POSITIVE SOLID TUMORS;
D O I：
10.1016/j.bulcan.2020.09.009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1085 / +
页数：2
相关论文
共 50 条
  • [31] Entrectinib for ROS1 fusion-positive NSCLC and NTRK fusion-positive solid tumours
    Lassen, Ulrik
    LANCET ONCOLOGY, 2020, 21 (02): : 193 - 194
  • [32] Entrectinib in NTRK fusion-positive (NTRK-fp) breast cancer: Updated data from STARTRK-2
    Lu, J.
    Blakely, C. M.
    Barve, M.
    Chung, C. H.
    Waqar, S. N.
    Hu, X.
    Delord, J-P.
    Krzakowski, M. J.
    Yonemori, K.
    Chen, D. T.
    Klingbiel, D.
    Heinzmann, S.
    Le Tourneau, C.
    ANNALS OF ONCOLOGY, 2022, 33 : S204 - S205
  • [33] Entrectinib: First Global Approval
    Zaina T. Al-Salama
    Susan J. Keam
    Drugs, 2019, 79 : 1477 - 1483
  • [34] Challenges in the Diagnosis of NTRK Fusion-Positive Cancers
    Gautschi, Oliver
    Bubendorf, Lukas
    Leyvraz, Serge
    Menon, Roopika
    Diebold, Joachim
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (07) : E107 - E109
  • [35] Efficacy and safety of entrectinib in patients with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumours
    Bazhenova, L.
    Liu, S. V.
    Lin, J. J.
    Lu, S.
    Drilon, A.
    Chawla, S. P.
    Fakih, M.
    Krzakowski, M.
    Paz-Ares, L.
    Blakely, C.
    Buchschacher, G. L., Jr.
    Cassier, P.
    Fan, Y.
    Folprecht, G.
    McCallum, S.
    Pitcher, B.
    Chen, D.
    Freund, R.
    Springfeld, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S598 - S599
  • [36] Larotrectinib: First Global Approval
    Scott, Lesley J.
    DRUGS, 2019, 79 (02) : 201 - 206
  • [37] Larotrectinib: First Global Approval
    Lesley J. Scott
    Drugs, 2019, 79 : 201 - 206
  • [38] Progression free survival of larotrectinib in patients with NTRK fusion-positive tumors: a systematic review
    Sumampow, M. M. A.
    Fu, R. C. E.
    Delvino, D.
    Albert, N.
    Danisha, P. A. C.
    Satcitta, N.
    ANNALS OF ONCOLOGY, 2024, 35 : S1353 - S1353
  • [39] Entrectinib demonstrates prolonged efficacy in an adult case of radiation-refractory NTRK fusion glioblastoma
    Grogan, Patrick T.
    Deming, Dustin A.
    Helgager, Jeffrey
    Ruszkiewicz, Theresa
    Baskaya, Mustafa K.
    Howard, Steven P.
    Robins, H. Ian
    NEURO-ONCOLOGY ADVANCES, 2022, 4 (01)
  • [40] A novel EML4-NTRK3 fusion in lung adenocarcinoma with dramatic response to entrectinib
    Batra, Ullas
    Nathany, Shrinidhi
    Sharma, Mansi
    Jain, Parveen
    Mehta, Anurag
    Bansal, Abhishek
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (07) : 2045 - 2047
12345